YES1 amplification confers trastuzumab–emtansine (T-DM1) resistance in HER2-positive cancer

被引：0
|
作者：
Lei Wang
Quanren Wang
Piaopiao Xu
Li Fu
Yun Li
Haoyu Fu
Haitian Quan
Liguang Lou
机构：
[1] Chinese Academy of Sciences,Shanghai Institute of Materia Medica
来源：
British Journal of Cancer | 2020年 / 123卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1000 / 1011
页数：11
相关论文
共 50 条
  • [1] YES1amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer
    Wang, Lei
    Wang, Quanren
    Xu, Piaopiao
    Fu, Li
    Li, Yun
    Fu, Haoyu
    Quan, Haitian
    Lou, Liguang
    BRITISH JOURNAL OF CANCER, 2020, 123 (06) : 1000 - 1011
  • [2] YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development
    Fujihara, Miwa
    Shien, Tadahiko
    Shien, Kazuhiko
    Suzawa, Ken
    Takeda, Tatsuaki
    Zhu, Yidan
    Mamori, Tomoka
    Otani, Yusuke
    Yoshioka, Ryo
    Uno, Maya
    Suzuki, Yoko
    Abe, Yuko
    Hatono, Minami
    Tsukioki, Takahiro
    Takahashi, Yuko
    Kochi, Mariko
    Iwamoto, Takayuki
    Taira, Naruto
    Doihara, Hiroyoshi
    Toyooka, Shinichi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (23)
  • [3] Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
    Boyraz, Baris
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Babacan, Taner
    Roach, Emir C.
    Kizilarslanoglu, Muhammet C.
    Petekkaya, Ibrahim
    Altundag, Kadri
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (04) : 405 - 414
  • [4] Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
    Hunter, Francis W.
    Barker, Hilary R.
    Lipert, Barbara
    Rothe, Francoise
    Gebhart, Geraldine
    Piccart-Gebhart, Martine J.
    Sotiriou, Christos
    Jamieson, Stephen M. F.
    BRITISH JOURNAL OF CANCER, 2020, 122 (05) : 603 - 612
  • [5] Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
    Francis W. Hunter
    Hilary R. Barker
    Barbara Lipert
    Françoise Rothé
    Géraldine Gebhart
    Martine J. Piccart-Gebhart
    Christos Sotiriou
    Stephen M. F. Jamieson
    British Journal of Cancer, 2020, 122 : 603 - 612
  • [6] Trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer
    Thibault, C.
    ONCOLOGIE, 2013, 15 (02) : 126 - 127
  • [7] Trastuzumab emtansine (T-DM1) for the treatment of HER2-positive breast cancer
    Sliwkowski, Mark X.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [8] STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer
    Wang, Lei
    Wang, Quanren
    Gao, Mingzhao
    Fu, Li
    Li, Yun
    Quan, Haitian
    Lou, Liguang
    CANCER SCIENCE, 2018, 109 (10): : 3305 - 3315
  • [9] Trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer and brain metastases
    Jacot, W.
    Pons, E.
    Guiu, S.
    Levy, C.
    Frenel, J-S
    Bachelot, T.
    D'Hondt, V.
    Firmin, N.
    Romieu, G.
    Thezenas, S.
    Dalenc, F.
    CANCER RESEARCH, 2016, 76
  • [10] Metastatic HER2-positive Breast Cancer New Perspectives with Trastuzumab Emtansine (T-DM1)
    Satzger, Ulla
    ONKOLOGIE, 2013, 36 (09): : 525 - 525
12345